Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 May 2017
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Biliary cancer
- Focus Therapeutic Use
- Acronyms FUGA-BT
- 09 May 2017 Planned End Date changed from 8 May 2018 to 8 Sep 2019.
- 30 Mar 2016 Status changed from recruiting to active, no longer recruiting.
- 13 May 2013 New source identified and integrated: University Hospital Medical Information Network - Japan record.